Clinical Trial

Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression. The main goals of the study are to: * Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab * Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab * Learn about the effect BT7480 has on the body and how BT7480 is cleared by the body * Learn about the side effects and effectiveness of BT7480 in patients with reduced kidney function
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2021-12-03; most recent amendment 2026-01-14.
Status change: Recruiting → Active, Not Recruiting 2025-01-31
Trial Details
NCT Number NCT05163041
Lead Sponsor BicycleTx Limited
Conditions Advanced Solid Tumor
Enrollment 200 participants
Start Date 2021-11-02
Primary Completion 2026-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-15